Discovery of Synergistic and Antagonistic Drug Combinations against SARS-CoV-2 In Vitro
Preprint
Abstract
COVID-19 is undoubtedly the most impactful viral disease of the current century, afflicting millions worldwide. As yet, there is not an approved vaccine, as well as limited options from existing drugs for treating this disease. We hypothesized that combining drugs with independent mechanisms of action could result in synergy against SARS-CoV-2. Using in silico approaches, we prioritized 73 combinations of 32 drugs with potential activity against SARS-CoV-2 and then tested them in vitro . Overall, we identified 16 synergistic and 8 antagonistic combinations, 4 of which were both synergistic and antagonistic in a dose-dependent manner. Among the 16 synergistic cases, combinations of nitazoxanide with three other compounds (remdesivir, amodiaquine and umifenovir) were the most notable, all exhibiting significant synergy against SARS-CoV-2. The combination of nitazoxanide, an FDA-approved drug, and remdesivir, FDA emergency use authorization for the treatment of COVID-19, demonstrate a strong synergistic interaction. Notably, the combination of remdesivir and hydroxychloroquine demonstrated strong antagonism. Overall, our results emphasize the importance of both drug repurposing and preclinical testing of drug combinations for potential therapeutic use against SARS-CoV-2 infections.Keywords
All Related Versions
- Published version: Molecular Therapy, 29 (2), 873.
This publication has 81 references indexed in Scilit:
- Interferon and Ribavirin Combination Treatment Synergistically Inhibit HCV Internal Ribosome Entry Site Mediated Translation at the Level of Polyribosome FormationPLOS ONE, 2013
- The Hepatitis C Virus (HCV) NS4B RNA Binding Inhibitor Clemizole Is Highly Synergistic with HCV Protease InhibitorsThe Journal of Infectious Diseases, 2010
- Trust, But Verify: On the Importance of Chemical Structure Curation in Cheminformatics and QSAR Modeling ResearchJournal of Chemical Information and Modeling, 2010
- Artemisinin-based combination therapies: a vital tool in efforts to eliminate malariaNature Reviews Microbiology, 2009
- Synergistic antiviral activity of acyclovir and vidarabine against herpes simplex virus types 1 and 2 and varicella-zoster virusAntiviral Research, 2006
- Potent Antiviral Synergy between Monoclonal Antibody and Small-Molecule CCR5 Inhibitors of Human Immunodeficiency Virus Type 1Antimicrobial Agents and Chemotherapy, 2006
- Theoretical Basis, Experimental Design, and Computerized Simulation of Synergism and Antagonism in Drug Combination StudiesPharmacological Reviews, 2006
- The synergistic effects of betulin with acyclovir against herpes simplex virusesAntiviral Research, 2004
- HIV Drug ResistanceNew England Journal of Medicine, 2004
- Intracellular distribution and effect of the antimalarial drug mefloquine on lysosomes of rat liverLiver International, 1992